DE69724970D1 - Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a - Google Patents

Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a

Info

Publication number
DE69724970D1
DE69724970D1 DE69724970T DE69724970T DE69724970D1 DE 69724970 D1 DE69724970 D1 DE 69724970D1 DE 69724970 T DE69724970 T DE 69724970T DE 69724970 T DE69724970 T DE 69724970T DE 69724970 D1 DE69724970 D1 DE 69724970D1
Authority
DE
Germany
Prior art keywords
mla
monophosphoryl lipid
type
hypersensitivity
treating hypersensitivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69724970T
Other languages
English (en)
Other versions
DE69724970T2 (de
Inventor
Jerry Dolovich
Terry Ulrich
S Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of DE69724970D1 publication Critical patent/DE69724970D1/de
Publication of DE69724970T2 publication Critical patent/DE69724970T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69724970T 1996-05-14 1997-05-08 Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a Expired - Lifetime DE69724970T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/645,672 US5762943A (en) 1996-05-14 1996-05-14 Methods of treating type I hypersensitivity using monophosphoryl lipid A
US645672 1996-05-14
PCT/US1997/007965 WO1997042947A1 (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid a

Publications (2)

Publication Number Publication Date
DE69724970D1 true DE69724970D1 (de) 2003-10-23
DE69724970T2 DE69724970T2 (de) 2004-07-22

Family

ID=24589990

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724970T Expired - Lifetime DE69724970T2 (de) 1996-05-14 1997-05-08 Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a

Country Status (11)

Country Link
US (1) US5762943A (de)
EP (1) EP0914114B1 (de)
JP (1) JP4105230B2 (de)
AT (1) ATE249824T1 (de)
AU (1) AU3121497A (de)
CA (1) CA2252604C (de)
DE (1) DE69724970T2 (de)
DK (1) DK0914114T3 (de)
ES (1) ES2205231T3 (de)
PT (1) PT914114E (de)
WO (1) WO1997042947A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086928B2 (ja) * 1997-02-13 2008-05-14 大日本住友製薬株式会社 タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9724531D0 (en) * 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
ES2229745T3 (es) * 1998-07-14 2005-04-16 Wyeth Holdings Corporation Composicionde adyuvante y vacuna que contienen monofosforil lipido a.
ES2259478T3 (es) * 1998-09-18 2006-10-01 Dynavax Technologies Corporation Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
EP1671646A3 (de) * 1998-09-18 2007-08-29 Dynavax Technologies Corporation Verfahren zur Behandlung von IgE- assoziierten Krankheiten und Zusammensetzungen zur Verwendung in diesen Verfahren
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
EA006233B1 (ru) 1999-05-13 2005-10-27 Уайт Холдингз Корпорейшн Комбинированные адъювантные композиции для усиления иммунного ответа у позвоночного животного
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
CN1606446A (zh) 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
BR0115271A (pt) * 2000-11-10 2005-12-13 Wyeth Corp Composição antigênica, método para incrementar a capacidade de uma composição antigênica em elicitar a resposta imunológica de um hospedeiro vertebrado, em elicitar linfócitos t citotóxicos em um hospedeiro vertebrado, em elicitar um efeito terapêutico ou profilático anti-câncer em um hospedeiro vertebrado, em moderar uma resposta alérgica em um hospedeiro vertebrado, e em prevenir ou tratar doença caracterizada por deposição amilóide em um hospedeiro vertebrado, e, formulação adjuvante
GB0120150D0 (en) * 2001-08-17 2001-10-10 Glaxosmithkline Biolog Sa Novel compounds
DE10359351A1 (de) 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US9724271B2 (en) * 2010-04-30 2017-08-08 Allovate, Llc Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA2935722A1 (en) * 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
KR20170141680A (ko) * 2015-05-01 2017-12-26 닛토덴코 가부시키가이샤 알레르기 백신 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (de) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmazeutische Präparate
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
KR900701304A (ko) * 1988-05-05 1990-12-01 루이즈 츄이 콜린스 에이미 사람 및/또는 동물용 알레르겐 탈감작제
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
JP2838800B2 (ja) * 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
AU3658093A (en) * 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens

Also Published As

Publication number Publication date
CA2252604C (en) 2009-09-08
ES2205231T3 (es) 2004-05-01
ATE249824T1 (de) 2003-10-15
JP4105230B2 (ja) 2008-06-25
EP0914114A1 (de) 1999-05-12
DK0914114T3 (da) 2003-10-20
DE69724970T2 (de) 2004-07-22
WO1997042947A1 (en) 1997-11-20
AU3121497A (en) 1997-12-05
EP0914114B1 (de) 2003-09-17
US5762943A (en) 1998-06-09
JP2000510844A (ja) 2000-08-22
PT914114E (pt) 2004-02-27
CA2252604A1 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
ATE249824T1 (de) Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE205713T1 (de) Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit
HUP0101139A2 (hu) Porított vakcinakészítmények transzdermális beadásra
BR9609743A (pt) Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
DE3486160T2 (de) Modifizierte lebende Pseudo-Rabies-Viren, diese enthaltende Impfstoffe gegen Pseudo-Rabies, Verfahren zur Herstellung und Verfahren zur Verwendung derselben.
ATE223702T1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
Brady et al. Autoregulation of periodontal ligament cell phenotype and functions by transforming growth factor-β1
DE69836268D1 (de) Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen
Shalit et al. Challenge of mast cells with increasing amounts of antigen induces desensitization
DE69530308D1 (de) Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
NO933261L (no) Blanding til forsterkning av immunforsvaret
BR9507846A (pt) Composição farmacéutica estável e fortemente concentrada de principio ativo da classe dos taxóides escolhido entre o docetaxol ou os derivados do docetaxol processo de preparação desta composição e utilização de uma solução congelada ou liofilizada
ATE219683T1 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
Dhalla et al. Calcium binding and ATPase activities of heart sarcolemma
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
FI956028A (fi) Estreenisteroidit ihmisen hypotalaamisen toiminnan muuttamisen neurokemiallisina initiaattoreina sekä tähän liittyvät farmaseuttiset koostumukset ja menetelmät
DE69429521T2 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
WO2002074922A3 (en) Compositions and methods for modulating an immune response
ATE197609T1 (de) Verfahren zur unterdrückung der immunantwort durch gentherapie
ATE439857T1 (de) Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition